Antimicrobial Resistance and the Development of Novel Pharmacological Agents

Abstract

Antimicrobial resistance (AMR) has emerged as one of the most significant global public health threats of the twenty-first century, compromising the effectiveness of antibiotics and other antimicrobial therapies used to treat infectious diseases. The widespread and often inappropriate use of antimicrobial agents in human medicine, veterinary practice, agriculture, and animal husbandry has accelerated the evolution and spread of resistant microorganisms. As a result, many bacterial, viral, fungal, and parasitic pathogens have developed mechanisms that reduce or eliminate the efficacy of existing treatments, leading to increased morbidity, mortality, prolonged hospital stays, and rising healthcare costs worldwide. The growing prevalence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) pathogens has created an urgent need for the development of novel pharmacological agents capable of overcoming resistance mechanisms. Recent advances in microbiology, molecular biology, medicinal chemistry, biotechnology, and artificial intelligence have facilitated the discovery and development of innovative therapeutic approaches.